Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 2 Results

Title
Intervention Indication Therapeutic Area Year Actions
Dabrafenib with trametinib for treating paediatric BRAF V600 mutated high-grade or low-grade glioma Dabrafenib (Tafinlar; GSK2118436; dabrafenib mesilate) , Trametinib (Mekinist; TMT212; GSK-1120212B; GSK1120212; JTP-74057; trametinib dimethyl sulfoxide) Glioma Neurological Cancer 2022 View  |  Download
Spartalizumab in addition to dabrafenib and trametinib for unresectable or metastatic BRAF V600 mutant melanoma – first‐line Dabrafenib (Tafinlar; GSK2118436; dabrafenib mesilate) , Spartalizumab (PDR001) , Trametinib (Mekinist; TMT212; GSK-1120212B; GSK1120212; JTP-74057; trametinib dimethyl sulfoxide) Melanoma Skin Cancer 2019 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications